Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Genentech licenses Relay’s SHP2 inhibitor

by Lisa M. Jarvis
December 17, 2020 | A version of this story appeared in Volume 98, Issue 48

 

Genentech will pay $75 million to license RLY-1971, Relay Therapeutics’ SHP2 inhibitor, which is in a Phase 1 trial to treat solid tumors. The deal gives Genentech access to a promising partner for its experimental inhibitor of KRAS G12C, a notoriously difficult target for cancer drugs. SHP2 helps KRAS cycle between its “on” and “off” states, and researchers think dampening its effects could increase the efficacy of KRAS inhibitors, which bind to the protein’s “off” state.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.